Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients

•The efficacy of LCT in bone oligometastatic lung adenocarcinoma is controversial.•This study provided real-world treatment outcomes in bone oligometastatic patients.•The current findings suggested that additional LCT could bring survival benefits.•LCT plus EGFR-TKIs could be a better therapeutic op...

Full description

Saved in:

Bibliographic Details
Published in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-09, Vol.135, p.138-144
Main Authors:	Hu, Fang, Li, Changhui, Xu, Jianlin, Guo, Jindong, Shen, Yinchen, Nie, Wei, Zheng, Xiaoxuan, Wang, Lixin, Zhang, Hai, Han, Baohui, Zhang, Xueyan
Format:	Article
Language:	eng
Subjects:	Bone oligometastases Epidermal growth factor receptor mutation Local consolidative therapy Tyrosine-kinase inhibitors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•The efficacy of LCT in bone oligometastatic lung adenocarcinoma is controversial.•This study provided real-world treatment outcomes in bone oligometastatic patients.•The current findings suggested that additional LCT could bring survival benefits.•LCT plus EGFR-TKIs could be a better therapeutic option in these patients. Whether epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) plus local consolidative therapy (LCT) has survival benefit over EGFR-TKIs alone in lung adenocarcinoma patients with EGFR mutation and bone oligometastases remains controversial. We conducted a retrospective study to assess the effects of LCT in lung adenocarcinoma patients with bone oligometastases and EGFR mutation. The primary endpoint was overall survival (OS); the secondary endpoints was progression-free survival (PFS). A total of 127 lung adenocarcinoma patients with EGFR mutation and bone oligometastases were assessed, including 65 patients received EGFR-TKIs alone (monotherapy group) and 62 patients received EGFR-TKIs plus local consolidative therapy (LCT) (combination group). Addition of LCT was associated with significantly longer OS (36.3 vs. 21.0 months, P = 0.01; hazard ratio [HR] = 0.537, 95% confidence interval [CI]: 0.360-0.801, p = 0.01) and PFS (14.0 vs. 8.1 months, P = 0.01; HR = 0.613, 95%CI: 0.427-0.879, p = 0.01) in the whole cohort. In lung adenocarcinoma patients with EGFR-mutation and bone oligometastases, LCT plus EGFR-TKIs therapy is associated with significantly longer OS and PFS compared with EGFR-TKIs therapy alone, indicating that LCT plus EGFR-TKIs therapy might be a better therapeutic option for this patient population.
ISSN:	0169-5002 1872-8332